300 related articles for article (PubMed ID: 31276431)
1. Glycoform-resolved FcɣRIIIa affinity chromatography-mass spectrometry.
Lippold S; Nicolardi S; Domínguez-Vega E; Heidenreich AK; Vidarsson G; Reusch D; Haberger M; Wuhrer M; Falck D
MAbs; 2019 Oct; 11(7):1191-1196. PubMed ID: 31276431
[TBL] [Abstract][Full Text] [Related]
2. Proteoform-Resolved FcɤRIIIa Binding Assay for Fab Glycosylated Monoclonal Antibodies Achieved by Affinity Chromatography Mass Spectrometry of Fc Moieties.
Lippold S; Nicolardi S; Wuhrer M; Falck D
Front Chem; 2019; 7():698. PubMed ID: 31709228
[TBL] [Abstract][Full Text] [Related]
3. Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography-mass spectrometry.
Lippold S; Knaupp A; de Ru AH; Tjokrodirijo RTN; van Veelen PA; van Puijenbroek E; de Taeye SW; Reusch D; Vidarsson G; Wuhrer M; Schlothauer T; Falck D
MAbs; 2021; 13(1):1982847. PubMed ID: 34674601
[TBL] [Abstract][Full Text] [Related]
4. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
[TBL] [Abstract][Full Text] [Related]
5. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
6. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
7. Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody.
Falck D; Thomann M; Lechmann M; Koeleman CAM; Malik S; Jany C; Wuhrer M; Reusch D
MAbs; 2021; 13(1):1865596. PubMed ID: 33382957
[TBL] [Abstract][Full Text] [Related]
8. Benchmarking glycoform-resolved affinity separation - mass spectrometry assays for studying FcγRIIIa binding.
Gstöttner C; Lippold S; Hook M; Yang F; Haberger M; Wuhrer M; Falck D; Schlothauer T; Domínguez-Vega E
Front Immunol; 2024; 15():1347871. PubMed ID: 38469305
[TBL] [Abstract][Full Text] [Related]
9. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
[TBL] [Abstract][Full Text] [Related]
10. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
[TBL] [Abstract][Full Text] [Related]
11. Restricted processing of CD16a/Fc γ receptor IIIa
Patel KR; Roberts JT; Subedi GP; Barb AW
J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
[TBL] [Abstract][Full Text] [Related]
12. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
[TBL] [Abstract][Full Text] [Related]
13. Effects of Glycan Structure on the Stability and Receptor Binding of an IgG4-Fc.
Kang H; Larson NR; White DR; Middaugh CR; Tolbert T; Schöneich C
J Pharm Sci; 2020 Jan; 109(1):677-689. PubMed ID: 31669606
[TBL] [Abstract][Full Text] [Related]
14. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
15. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
[TBL] [Abstract][Full Text] [Related]
16. CD16a with oligomannose-type
Subedi GP; Barb AW
J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
[TBL] [Abstract][Full Text] [Related]
17. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
18. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods.
Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M
MAbs; 2015; 7(4):732-42. PubMed ID: 25996192
[TBL] [Abstract][Full Text] [Related]
19. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.
Chung AW; Crispin M; Pritchard L; Robinson H; Gorny MK; Yu X; Bailey-Kellogg C; Ackerman ME; Scanlan C; Zolla-Pazner S; Alter G
AIDS; 2014 Nov; 28(17):2523-30. PubMed ID: 25160934
[TBL] [Abstract][Full Text] [Related]
20. Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding.
Lu X; Machiesky LA; De Mel N; Du Q; Xu W; Washabaugh M; Jiang XR; Wang J
Sci Rep; 2020 Jan; 10(1):383. PubMed ID: 31941950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
